Phase 2 Myeloma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 or older, of any sex or gender
- People who have been diagnosed with multiple myeloma based on internationally recognised diagnostic guidelines (IMWG criteria)
- People who have also been diagnosed with a condition called AL amyloidosis, confirmed through specific laboratory tests on tissue samples (including a Congo red stain test and at least one additional test such as immunohistochemistry, mass spectrometry, or electron microscopy)
- People who have a detectable level of disease that can be measured at the start of the trial
- People who have been newly diagnosed and have not yet received any treatment targeting plasma cells
- People whose blood and organ function test results meet specific minimum levels — including blood cell counts, liver function, kidney function, and calcium levels (confirm with trial site for exact values)
- People who are able and willing to use at least two effective methods of contraception throughout the study, if there is any possibility of pregnancy
- People who are willing to sign a consent form confirming they understand and agree to participate
Who may not be able to join:
- People who have previously received any treatment for myeloma or who have had a stem cell transplant
- People who have a related but different blood or protein disorder, such as MGUS, smouldering myeloma, AL amyloidosis without myeloma, Waldenström macroglobulinemia, plasma cell leukaemia, POEMS syndrome, or another cancer diagnosed within the past three years
- People who currently have an active infection or an autoimmune disease
- People with diabetes, high blood pressure, or other ongoing health conditions that are not well controlled
- People who are currently pregnant or breastfeeding
- People who are already taking part in another clinical intervention study
- People whom the trial doctor considers unsuitable for participation for any other reason
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Peng Liu, Fudan University
Phone: +86-021-64041990
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
1-Year Progression-Free Survival (PFS) Rate
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.